LAUSR

Pre-exposure prophylaxis (PrEP) has become an increasingly popular means of preventing HIV transmission, but the only currently approved form requires users to take a daily pill. Long-acting forms of PrEP could offer a simpler regimen, potentially improving adherence and effectiveness. One potential concern, however, is how clinicians could respond to side effects that emerge after a longacting form of PrEP is delivered; at present, formulations in late-stage development cannot be removed from the body once they are injected. Recently, researchers published findings from a preclinical study of a novel type of ultra-long-acting, removable PrEP in Nature Communications [1].